[Skip to Content]
[Skip to Content Landing]
March 12, 1949


Author Affiliations

Durham, N. C.

JAMA. 1949;139(11):733-734. doi:10.1001/jama.1949.02900280049024

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  The publication of a report by Drs. Lasser, Rosenthal and Loewe of a death following the use of tetraethylammonium chloride (etamon chloride®) in The Journal of January 15, page 153, makes it seem advisable to call attention to the means available for controlling the effects of this drug with neostigmine (prostigmine®). It happened that such interruption of the effects of etamon® by neostigmine was mentioned in the report of the Council on Pharmacy and Chemistry which followed immediately the case report referred to above (Grimson, K. S.; Hendrix, J. P., and Reardon, M. J.: J. A. M. A. 139: 154 [Jan. 15] 1949).Tetraethylammonium chloride now is in widespread use, and it is to be expected that occasional severe reactions in the form of vascular collapse, as previously reported, will occur. This drug blocks the transmission of nerve impulses through autonomic ganglions, and among other effects, loss

First Page Preview View Large
First page PDF preview
First page PDF preview